An Open-Label Pilot Study on Macumax Supplementation for Dry-Type Age-Related Macular Degeneration.

ABSTRACT: Age-related macular degeneration (AMD) is one of the most widespread degenerative disorders in elderly people. A 90-day, open-label clinical study was conducted in 40 patients, aged 50 years or older, with early-stage dry-type AMD to evaluate the safety and efficacy of Macumax^®, a novel mixture of a phyto-mineral nutritional supplement containing ZeaLutein^® (consisting of lutein, zeaxanthin, and piperine), extracts of bilberry, saffron, and zinc monomethionine. Subjects received one capsule of the supplement twice daily for 90 days. The treatment measures included physical examination, vital signs, and assessment of subjective and objective symptoms at baseline and after treatment. For efficacy assessment, baseline values were compared with the values after treatment

SUBMITTER: Majeed M 

PROVIDER: S-EPMC8140349 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature